Figure 1

Treatment with CCI-779 or CCI-779 plus IFN-γ reduced kidney tumor burden in Tsc2^+/- mice. The cohorts treated with CCI-779 received 8 mg/kg by IP injection Monday through Friday for two months at the indicated ages. The cohorts treated with both agents received 8 mg/kg CCI-779 and 20,000 units IFN-γ by IP injection Monday through Friday for two months at the indicated ages. Severity of kidney disease was quantified both by counting the total number of cystadenomas and by scoring all the cystadenomas found. Average number of cystadenomas per kidney for indicated treatment cohort shown in bar graph (a) and table (c) format. Average cystadenoma score per kidney for indicated treatment cohort shown in bar graph (b) and table (d) format. Red error bars denote a statistically significant difference (P < 0.05) relative to untreated. "Both" in panels a-d refers to a combination of CCI-779 and IFN-γ. To illustrate the timing of kidney lesion genesis in untreated Tsc2^+/- mice, graphs of average number of cystadenomas per kidney (e) and average cystadenoma score per kidney (f) are shown for cohorts of mice at different ages (3, 7 and 11 months; n = 6 mice for each age cohort). The asterisks in panels e and f indicate that the severity of kidney disease in untreated cohorts at 3 months and 11 months differs significantly from disease severity at 7 months (t-test, P ≤ 0.05).